Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes

Current Cardiology Reports

Volumn 18, Issue 3, 2016, Pages 1-5

  Teleb, Mohamed ^a   Popp Switzer, Maryna ^a   Elhanafi, Sherif ^b   Elfar, Ahmed ^c   San Juan, Zinnia T ^d  

^a Paul L Foster School of Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HARTFORD HOSPITAL   (United States)

^d INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

Cardiovascular events; Cardiovascular mortality; Diabetes mellitus; Hypoglycemia; Type 1 DM

Indexed keywords

HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DISEASE CONTROL; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; METABOLISM; MORTALITY;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84958778664     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-016-0700-6     Document Type: Review

References (20)

1. Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014;37:3336–44.
2. Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;12:156.
3. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29:798–804.
4. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–82. This population study of type 1 diabetes showed the relationship of cardiovascular risk to glycemic control in a graduated fashion.
5. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48:643–8.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
8. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630–3.
9. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:34i-43i.
10. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
11. Abraira C, Duckworth WC, Moritz T, Group V. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. 2009;11:150–6.
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
13. Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206. This study demonstrated emergence of benefit in terms of delay in time to first cardiovascular event in type 2 diabetics with high risk for cardiovascular complications 10 years after tight glycemic control intervention.
14. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
15. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
16. Writing Group for the DERG, Orchard TJ, Nathan DM, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313:45–53. This study demonstrated that 27 years after an initial period of tight glycemic control, all-cause mortality was lower in the intervention group of type 1 diabetes.
17. Lachin JM, Orchard TJ, Nathan DM, Group DER. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:39–43. This follow up study demonstrated decrease in cardiovascular mortality in intensive glucose control with a decrease in markers for atherosclerosis.
18. Nystrom T, Holzmann MJ, Eliasson B, Kuhl J, Sartipy U. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. J Am Coll Cardiol. 2015;66:535–43.
19. Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2015;3:198–206. This study demonstrated women with type 1 diabetes are at a higher risk for vascular complications and have higher mortality compared to men.
20. Schoenaker DA, Simon D, Chaturvedi N, Fuller JH, Soedamah-Muthu SS, Group EPCS. Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB prospective complications study. J Clin Endocrinol Metab. 2014;99:800–7. This study demonstrated U-shape curve between mortality and HbA1c level.